Invention Grant
US07696316B2 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor
失效
21910,5563,4505,2504,15977,14760,25501,17903,3720,21529,26176,26343,5666,18610,33217,26967，H1983，M1983,38555或593分子及其用途
- Patent Title: 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor
- Patent Title (中): 21910,5563,4505,2504,15977,14760,25501,17903,3720,21529,26176,26343,5666,18610,33217,26967，H1983，M1983,38555或593分子及其用途
-
Application No.: US11583766Application Date: 2006-10-19
-
Publication No.: US07696316B2Publication Date: 2010-04-13
- Inventor: Rosana Kapeller-Libermann , John Joseph Hunter , Rachel E. Meyers , Laura A. Rudolph-Owen , Rory A. J. Curtis , Peter J. Olandt , Fong-Ying Tsai , Katherine M. Galvin , Miyoung Chun , Mark J. Williamson , Inmaculada Silos-Santiago , Rajasekhar Bandaru
- Applicant: Rosana Kapeller-Libermann , John Joseph Hunter , Rachel E. Meyers , Laura A. Rudolph-Owen , Rory A. J. Curtis , Peter J. Olandt , Fong-Ying Tsai , Katherine M. Galvin , Miyoung Chun , Mark J. Williamson , Inmaculada Silos-Santiago , Rajasekhar Bandaru
- Applicant Address: US MA Cambridge
- Assignee: Millennium Pharmaceuticals, Inc.
- Current Assignee: Millennium Pharmaceuticals, Inc.
- Current Assignee Address: US MA Cambridge
- Main IPC: C07K14/00
- IPC: C07K14/00 ; C07H21/04 ; C12P21/04 ; C12P21/06
Abstract:
The invention provides isolated nucleic acids molecules, designated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 gene has been introduced or disrupted. The invention still further provides isolated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 proteins, fusion proteins, antigenic peptides and anti-21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
Public/Granted literature
Information query
